|
楼主 |
发表于 2008-12-16 09:49:57
|
显示全部楼层
40-5-第五节 小 结
肺动脉高压是风湿病的一个常见的肺部并发症,可见于几乎所有的风湿病,主要见于系统性硬化、混合性结缔组织病和系统性红斑狼疮。合并风湿病的肺动脉高压与原发性肺动脉高压在病理、临床和治疗方面有很多相似之处。肺动脉高压的预后较差,前列环素及其类似物,以及其他新治疗的出现,使肺动脉高压的预后得到了明显改善。 6 _; C& n/ X9 ^5 w2 Y7 D9 ~! M$ _
(徐凯峰)1 ^% N& ?! X& B& a. ?) r
参考文献0 r9 [: P8 L2 X2 A( x; S2 ?
5 p5 Z5 h( i$ Z* f8 O3 K
高天明,肺动脉高压和原发性肺动脉高压.见:蔡柏蔷主编,21世纪医师丛书:呼吸内科分册.北京:中国协和医科大学出版社,2000.477一489. 4 _5 [4 B+ s7 u A& k( c9 N
* d% h/ C7 o% h8 n
Alpert MA, Pressly TA, Mukerji V, et al. Short- and long-term hemodynamic effects of captopril in patients with pulmonaryhypertension and selected connective tissue disease. Chest, 1992.102:1407一1412 , [3 u/ V7 b+ Z2 h+ G9 u
: H0 Y$ {5 ?6 E- T9 q/ M
Badesch DB, Tapson VF, McGoon MD, et al. Continuousintravenous epoprostenol for pulmonary hypertension due to thescleroderma spectrum of disease. A randomized, controlled trial.Ann Intern. Med,2000.132:425一434 1 V# G% F" M I# g+ O5 W' j+ S( P
" t# R# t3 y+ C: O& Z
Barst RJ, Rubin LJ,Long WA, et al. A comparison of con-tinuous intravenous epoprostenol (prostacyclin) with conventionaltherapy for primary pulmonary hypertension. The Primary Pul-monary Hypertension Study Group. N Engl J Med, 1996. 334:296一302 " V/ w& R5 w! h. U
! Y' {4 A3 P3 Y" N8 t1 w+ ^2 ?
Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma.Chest,1996.110:1515一1519 " m3 r/ p+ g I9 T( M j" n
& a4 V" b" { R+ }
British Cardiac Society Guidelines and Medical Practice Com-mittee. Recommendations on the management of pulmonary hy-pertension in clinical practice. Heart, 2001.86(Suppl)I:I1一13 " ]; r4 q/ v1 W; T6 V( w" W
$ Z- w4 l4 J* y
Burdt MA, Hoffman RW, Deutscher SL, et al. Long-termoutcome in mixed connective tissue disease: longitudinal clinicaland serologic findings. Arthritis Rheum, 1999. 42: 899一909 & m$ L6 i3 A+ S1 J
9 Y( F# p. g! M' i4 F( A6 j4 M Channick RN, Simonneau G, Sitbon O, et al. Effects of thedual endothelin-receptor antagonist bosentan in patients with pul-monary hypertension: a randomised placebo-controlled study.Lancet,2001.358:1119一1123 - o; i1 l* J" c6 b e+ o
- h, n0 p' P- d( c, x! G Dawson JK, Goodson NG, Graham DR, et al. Raised pulmonary artery pressures measured with Doppler echocardiographyin rheumatoid arthritis patients. Rheumatology(Oxford),2000.39:1320一1325 6 w4 [$ i2 U& u( Y% ]/ k( R
6 W0 l: b' x* [9 o1 }% N# q Espinosa G, Cervera R, Font J, et al. The lung in the an-tiphospholipid syndrome. Ann Rheum Dis,2002.61 :195一198 # P7 P5 ]" K+ m1 u- h8 a
6 ]; |( {0 ?, w/ R$ J1 \
Galie N, Manes A, Branzi A. Medical therapy of pulmonaryhypertension. The prostacyclins. Clin Chest Med, 2001.22:529一37 + p( p7 J" `* B' e. Z
0 c r& W4 G5 G! V# {5 K+ m: }' z' P Gurubhagavatula 1, Palevsky HI. Pulmonary hypertension insystemic autoimmune disease. Rheum. Dis Clin North Am, 1997.23:365一394
) q2 ^) x7 `$ z7 U5 ^3 c5 R( S+ ]2 s. d2 H
Hinderliter AL, Willis PW, Barst RJ,et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographicmeasures of right ventricular structure and function in primarypulmonary hypertension. Primary Pulmonary Hypertension StudyGroup. Circulation, 1997.95:1479一1486
* x! u# F) a9 C" j0 z+ @4 }
6 K! U3 A- o- [8 k( } Hoeper MM, Galie N, Simonneau G, et al. New treatmentsfor pulmonary arterial hypertension. Am J Respir Crit Care Med,2002.165:1209一1216
- t& L# h% @9 l; ?/ u
% m; w9 E1 J+ ?' `* G Hoeper MM, Schwarze M, Ehlerding S, et al. Long-termtreatment of primary pulmonary hypertension with aerosolized ilo-prost, a prostacyclin analogue. N Engl J Med,2000.342:1866一1870 ' Z* W8 J. o. v+ K! h/ k" e
2 @, A' t! O7 e: ?3 v Horn EM, Barst RJ, Poon M. Epoprostenol for treatment ofpulmonary hypertension in patients with systemic lupus erythe-matosus. Chest,2000.118:1229一1230
3 J% }# O$ O' I: f' i& [' Q, Y9 j0 E8 |- Q) M3 l
Humbert M, Sanchez O, Fartoukh M, et al. Short-termand long-term epoprostenol (prostacyclin) therapy in pulmonaryhypertension secondary to connectivetissue diseases: results of apilot study. Eur Respir J,1999.13:1351一1356 # i0 ^, W, y7 B
% d: s2 G x, F8 Y) m5 P Klings ES, Hill NS, leong MH, et al. Systemic sclerosis-as-sociated pulmonary hypertension: short-and long-term effects ofepoprostenol (prostacyclin).Arthritis Rheum, 1999. 42: 2638-2645 8 T* X3 i; ]. D. S+ {' J x) U# Z: t
! r1 S6 E" w) M8 \0 L: s Koh ET, Lee P, Gladman DD, et al. Pulmonary hyperten-sion in systemic sclerosis: an analysis of 17 patients. Br. JRheumatol,1996.35:989一993
# s4 v; G d, o$ ^' C: j- X- j( i2 ?' O* Y4 n" C V! k
Kunieda T. Diagnosis and treatment of pulmonary hyperten-sion associated with collagen diseases. Intern Med,2000. 39:280一282 % W/ K U8 S/ D
Launay D, Hachulla E, Hatron PY, et al. Pulmonary hyper-tension screening in systemic scleroderma: a cohort study of 67patients. Rev Med Interne,2001.22:819一829
* M0 S1 ], M" g) A Q
9 V' r2 b9 M# `7 ?% }( J( A$ N& A Li EK, Tam LS. Pulmonary hypertension in systemic lupuserythematosus: clinical association and survival in 18 patients. JRheumato1,1999.26:1923一1929
. F- b! L4 f4 K+ l m/ U9 I4 L2 f% U3 Q. z
McLaughlin VV, Genthner DE, Panella MM, et al, Reduc-tion in pulmonary vascular resistance with long-term epoprostenol(prostacyclin) therapy in primary pulmonary hypertension. NEngl J Med,1998. 338:273一277
2 \5 Y5 k1 d8 G6 Y: E6 d1 c
- w5 o `! W/ P V: ]+ W McLaughlin VV, Genthner DE, Panella MM, et al. Com-passionate use of continuous prostacyclin in the management ofsecondary pulmonary hypertension: a case series. Ann InternMed,1999.130:740一743
: ?& \. W8 @* z2 H- E% x+ s) r; @6 i, I8 \$ M& I9 @; v- [
Murata I, Takenaka K, Yoshinoya S, et al. Clinical evalua-tion of pulmonary hypertension in systemic sclerosis and relateddisorders. A Doppler echocardiographic study of 135 Japanese pa-tients. Chest, 1997.111:36一43 , z6 F+ ?+ y7 S8 f0 T" v* H2 _
; L1 u! p0 H, ?: @0 h
Nishimaki T, Aotsuka S, Kondo H, et al. Immunologicalanalysis of pulmonary hypertension in connective tissue diseases. JRheumato1,1999. 26:2357一2362
9 Q% _0 _- i; A+ `# q! `6 P) \+ P( H9 ?2 i
Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension sec-ondary to lung fibrosis. Am J Respir Crit Care Med,1999. 160:600一607
* K$ S B2 S# l1 W( C% o6 \& h1 o8 k5 W3 B; F
Ooiwa H, Miyazawa T, Yamanishi Y, et al. Successfultreatment of systemic lupus erythematosus and pulmonary hyper-tension with intravenous prostaglandin 12 followed by its oral ana-logue. Intern Med,2000.39:320一323
3 @8 \3 m. _# ?! m) Q$ f6 R- Q: H% T/ m
Pan TL, Thumboo J, Boey ML. Primary and secondary put-monary hypertension in systemic lupus erythematosus. Lupus,2000.9:338一342 / s6 N, |6 S. V8 L+ f1 l$ H
) d: Z; a! e+ i- ]' Z$ s1 q$ ^# j
Robbins IM, Gaine SP, Schilz R, et al. Epoprostenol fortreatment of pulmonary hypertension in patients with systemic lu-pus erythematosus. Chest,2000.117:14一18
! e" M: L' O) P5 @" r3 O f+ U4 ]& g, _2 Q
Rubin LJ, Badesch DB, Barst RJ,et al. Bosentan therapyfor pulmonary arterial hypertension. N Engl J Med, 2002. 346:896一903
8 i( l7 u$ a& a! X/ c Sanchez O, Humbert M, Sitbon O, et al. Treatment of pul-monary hypertension secondary to connective tissue diseases.Thorax, 1999.54:273一277
' r( e+ f( n9 N
# U x$ `. b- K" o, ~* X; j" g Sato N, Kyotani S, Sakamaki fi, et al. Pulmonary throm-boendarterectomy for chronic pulmonary thromboembolism inthree patients with systemic lupus erythematosus and antiphos-pholipid syndrome. Nihon Kokyuki Gakkai Zasshi, 2000. 38:958 一964
1 a. `+ }( V+ h G' [0 R9 L0 [5 l ]" y/ E6 f! y
Simonneau G, Barst RJ,Galie N, et al. Continuous subcuta-neous infusion of treprostinil, a prostacyclin analogue, in patientswith pulmonary arterial hypertension: a double-blind, random-ized, placebo-controlled trial. Am J Respir Crit Care Med,2002.165:800一804 , R# D# C3 [0 A* J7 W8 @
Vizza CD, Sciomer S, Morelli S, et al. Long term treatmentof pulmonary arterial hypertension with beraprost, an oral prosta-cyclin analogue. Heart,2001.86:661一665 . s) j+ W l* N3 `2 T
7 Y, ^" r- n7 O$ v3 {
Wensel R, Opitz CF, Ewert R, et al. Effects of iloprost in-halation on exercise capacity and ventilatory efficiency in patientswith primary pulmonary hypertension. Circulation, 2000. 101:2388一2392 0 n; }2 O0 @! b6 I
8 P& v5 E7 t- k* [3 C5 G D# O
Winslow TM, Ossipov MA, Fazio GP, et al. Five-year fol-low-up study of the prevalence and progression of pulmonary by-pertension in systemic lupus erythematosus. Am Heart J, 1995.129:510一515 : O$ f: X+ J2 d. |" E0 M5 X
0 U( {" z$ o2 H7 K Yamane K, Ihn H, Asano Y, et al. Clinical and laboratoryfeatures of scleroderma patients with pulmonary hypertension.Rheumatology(Oxford), 2000.39:1269一1271 |
|